Patents Examined by Ronald T Niebauer
-
Patent number: 12162955Abstract: The present invention relates to series of peptidomimetic compounds selectively targeting CBX8 of polycomb chromobox protein homolog proteins. Pharmaceutical compositions of those compounds and methods of using them in the treatment of diseases involved CBX8 pharmacology, including various cancers and leukemia, by administering therapeutically effective amounts of such compound alone or together with other therapeutics, are within the scope of this disclosure.Type: GrantFiled: January 31, 2023Date of Patent: December 10, 2024Assignee: Purdue Research FoundationInventors: Casey J. Krusemark, Emily C. Dykhuizen, Sijie Wang
-
Patent number: 12162954Abstract: The present invention relates to a method for preparing etelcalcetide hydrochloride (etelcalcetide HCL). A first peptide is de-protected and cleaved from a solid support by a first solution system, for obtaining a second peptide, followed by coupling an activated L-Cys-OH to the second peptide in the second solution system for forming a TFA salt of etelcalcetide that is not or hardly dissolved in the second solution system. After purification by column chromatography, the TFA salt of etelcalcetide can be converted to etelcalcetide HCL using a third solution system that excludes hydrogen chloride during a real-time monitoring salt exchange step. The present method provides a simplified process and the etelcalcetide HCL with high purity and yield, for being advantageously applied in mass production of etelcalcetide HCL.Type: GrantFiled: July 18, 2022Date of Patent: December 10, 2024Assignee: KRISAN BIOTECH Co., Ltd.Inventors: Ya-Chun Chang, Shih-Wei Li
-
Patent number: 12139556Abstract: The present invention relates to natural or natural-like analogues of insect kinin neuropeptide [Hy]-RQKTVFSSWG-[NH2] (SEQ ID NO:2) having activity against insects, for example hemipteran, dipteran, lepidopteran and/or blattodean insects, such as aphids, moths and fruit flies, and their use as insect control agents (e.g. insecticides) and plant protection agents.Type: GrantFiled: October 23, 2023Date of Patent: November 12, 2024Assignee: Solasta Bio LimitedInventors: Julian A. T. Dow, Shireen A. Davies, Yousef Abul-Haija, Lewis Archibald
-
Patent number: 12139557Abstract: A synthetic peptide sp2 has the amino acid sequence shown in SEQ ID No: 1. sp2 has obvious anti-tumor growth activity on xenograft tumours such as subcutaneous human pancreatic cancer, human cervical cancer, and human ovarian cancer in nude mice, with a dose-effect and time-effect relation; and has the effect of delaying metastasis and prolonging the survival time of nude mouse having in situ transplantation of human pancreatic cancer and lung adenocarcinoma. After the animals were given intravenous injection of sp2 at a dose of 2000 mg/kgBW, no toxicity reaction and death were observed. The applications of sp2 also include: (1) preventing and/or treating of tumor; (2) inhibiting proliferation and/or growth and/or invasion of tumor cells; (3) enhancing the anti-tumor immune response; (4) inducing tumor cell differentiation; (5) preparing anti-tumor drugs; (6) inhibiting tumor telomerase activity; and (7) regulating the tumor cell cycle.Type: GrantFiled: June 30, 2022Date of Patent: November 12, 2024Assignee: TAIAN CITY QIHANG BIOTECHNOLOGY CO.Inventors: Wanqin Zhang, Yintian Li, Xuewen Ji, Limei Zhao
-
Patent number: 12129312Abstract: Disclosed in the present invention are a peptide compound, an application thereof, and a composition containing the same. Provided in the present invention are a peptide compound represented by formula I, a pharmaceutically acceptable salt thereof, a tautomer thereof, a solvate thereof, a crystal form thereof, or a prodrug thereof. The compound has good stability and good activity.Type: GrantFiled: June 27, 2018Date of Patent: October 29, 2024Assignee: XDCEXPLORER (SHANGHAI) CO., LTD.Inventors: Yan Wang, Yvonne Angell, Yun Wu, Manhua Li, Yonghan Hu
-
Patent number: 12129222Abstract: It is an object of the present invention to introduce carboxylic acid-functionalities suitable for coupling into the denatonium structure by means of simple synthesis, namely the synthesis of bitter principle derivatives based on the denatonium structure according to formula 1: For example, according to the invention, lidocaine derivatives may be reacted with carboxylated benzyl halogenides. The carboxylated denatonium derivatives of the present invention are especially applied in medicine, biology, medical engineering as well as cosmetics, the pharmaceutical, chemical, and foodstuff industry.Type: GrantFiled: August 11, 2017Date of Patent: October 29, 2024Assignee: Julius-Maximilians-UniversitaetInventors: Ralf Wyrwa, Claudia Rode, Thomas Seemann, Lorenz Meinel, Jennifer Ritzer, Matthias Schnabelrauch
-
Patent number: 12076367Abstract: A fusion protein is described, comprising a first N-terminal signal peptide sequence, a second peptide sequence C-terminal to the signal peptide sequence, and a third peptide sequence C-terminal to the second peptide sequence; wherein one of the second peptide sequence and the third peptide sequence is an RdCVF-short peptide sequence and the other is a hydrophilic peptide sequence. After translation the signal peptide is cleaved, leaving a fusion protein comprising the second peptide sequence and the third peptide sequence minus the signal peptide. Also described are nucleic acids and expression vectors encoding the fusion protein, cells comprising the nucleic acid or expression vector, as well as methods of treatment and uses of the fusion protein, nucleic acid, and expression vector. The fusion protein can be produced in vitro by culturing the cells of this invention under conditions allowing for expression and secretion of the encoded fusion protein, and isolating the fusion protein from the cell culture.Type: GrantFiled: February 10, 2021Date of Patent: September 3, 2024Assignee: Pharma Cinq, LLCInventors: Tianci Luo, Jun Zhang
-
Patent number: 12076368Abstract: The present invention relates to methods for treatment or prevention of liver, biliary tract, and pancreatic disorders by administering one or more defensins. Included within the scope of the disclosure is also treatment of certain metabolic disorders.Type: GrantFiled: April 28, 2017Date of Patent: September 3, 2024Assignee: Novozymes A/SInventors: Peter Nordkild, Soren Kjaerulff
-
Patent number: 12072338Abstract: The invention provides pharmaceutical compositions comprising at least a portion of a chemokine receptor or a G-protein coupled receptor. The pharmaceutical composition of the invention may be used for altering immune system functioning, for example, to treat an immune system disorder, such as an autoimmune disease, multiple sclerosis, transplant rejection, psoriasis, rheumatoid arthritis and asthma. The invention also provides peptides that may be used individually, in combination with, or in combination with other therapeutic agents such as steroid, non-steroid anti-inflammatory drug, immune modulator or immune suppressor.Type: GrantFiled: October 9, 2009Date of Patent: August 27, 2024Assignee: PROTAGONISTS LTD.Inventors: Chai Ezerzer, Nicholas Harris
-
Patent number: 12065511Abstract: The disclosure provides compositions and methods relating to aromatic-cationic peptides. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to subjects in need thereof. For example, the peptides may be administered to subjects in need of a mitochondrial-targeted antioxidant.Type: GrantFiled: March 13, 2020Date of Patent: August 20, 2024Assignee: STEALTH BIOTHERAPEUTICS INC.Inventors: D. Travis Wilson, Marc W. Andersen, Elizabeth Mead
-
Patent number: 12064514Abstract: The present invention is directed to peptisomes, including nanopeptisomes, which have a perfluorocarbon liquid core containing a perfluorocarbon liquid and a cargo, such as a therapeutically active agent, dispersed in the perfluorocarbon. liquid, and a plurality of amphiphilic peptide molecules surrounding the perfluorocarbon liquid core, wherein the amphiphilic peptide is represented by Formula (I) HB-CL-HP wherein HB is a fluorinated hydrophobic block, such as a fluorinated hydrophobic amino acid sequence, CL is a cross-linking motif, and HP is a hydrophilic amino acid sequence. The present invention is also directed to methods of use of the amphiphilic peptides and peptisomes, such as nanopeptisomes, to deliver a cargo, such as a therapeutically active agent, to a cell, Q wherein the cell may be in vitro, ex vivo, or in vivo.Type: GrantFiled: July 30, 2018Date of Patent: August 20, 2024Assignees: THE PENN STATE RESEARCH FOUNDATION, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, OFFICE OF TECHNOLOGY TRANSFER, NATIONAL INSTITUTES OF HEALTHInventors: Joel P. Schneider, Scott H. Medina
-
Patent number: 12037417Abstract: The present invention relates to an IgG-binding peptide comprising a ligand capable of binding to a radioactive metal nuclide, an IgG-binding peptide labeled with a radioactive metal nuclide, a conjugate of the IgG-binding peptide and IgG, and a radionuclide imaging agent or a diagnostic agent for cancer comprising the IgG-binding peptide or the conjugate, etc.Type: GrantFiled: June 12, 2017Date of Patent: July 16, 2024Assignee: Kagoshima UniversityInventors: Yuji Ito, Yoshinari Shoyama, Akio Hayashi, Norihito Nakata
-
Patent number: 12024571Abstract: The present specification provides an anti-EpoR peptide. A peptide having the structure represented by formula (I): V-SCH(A1)(A2)(A3)(A4)(A5)(A6)v(A7)(A8)-X2 (wherein X1 is the amino terminal side of the peptide; X2 is the carboxy terminal side of the peptide; A1 is M or F, phenylglycine or phenethylglycine optionally substituted by a halogen atom or a hydroxyl group; A2 is A, d-alanine or G; A3 is P, homoproline or A; A4 is M, L, A or I; A5 is T or A; A6 is M or W, F, Y, ?-homotryptophan, ?-naphthylalanine, ?-naphthylalanine, or quinolylalanine optionally substituted by methyl or a halogen atom; A7 is C, homocysteine, or penicillamine; and A8 is K, R or absent) is provided.Type: GrantFiled: September 12, 2019Date of Patent: July 2, 2024Assignee: Epo-Med Inc.Inventors: Hiroyuki Kouji, Yoshiko Yasuda, Akira Katoh, Hiroshi Ochi
-
Patent number: 12018095Abstract: An object of the present invention is to provide a cell penetrating peptide having a penetrating ability into cells. The present inventors provided a cell penetrating peptide consisting of the amino acid sequence of SEQ ID NO: 1, a cell penetrating peptide consisting of the amino acid sequence of SEQ ID NO: 2 and a cell penetrating peptide consisting of the amino acid sequence of SEQ ID NO: 3; and a complex comprising any one of the cell penetrating peptide and a functional molecule.Type: GrantFiled: June 30, 2022Date of Patent: June 25, 2024Assignees: Astellas Pharma Inc., National Center for Global Health and Medicine, Hiroshima UniversityInventors: Hideki Endo, Yukihito Ishizaka, Akira Ishiguro, Tomoki Takashina, Takashi Yamamoto, Tetsushi Sakuma
-
Patent number: 12012466Abstract: The present invention provides compounds of formula (I) wherein X1 to X8 and R1 to R8 are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is concerned with the manufacture of the compounds of formula (I), pharmaceutical compositions comprising them and their use as medicaments for the treatment of diseases and infections caused by Acinetobacter baumannii.Type: GrantFiled: July 15, 2021Date of Patent: June 18, 2024Assignee: Hoffmann-La Roche Inc.Inventors: Alexander Alanine, Julien Beignet, Konrad Bleicher, Bernhard Fasching, Hans Hilpert, Taishan Hu, Dwight MacDonald, Stephen Jackson, Sabine Kolczewski, Carsten Kroll, Adrian Schaeublin, Hong Shen, Theodor Stoll, Helmut Thomas, Amal Wahhab, Claudia Zampaloni
-
Patent number: 11999805Abstract: Specific and broad-spectrum inhibitory peptides to CRISPR Cas9 variants (SpyCas9, SauCas9, and CjeCas9) are disclosed. A method of making and using these peptides with therapeutic CRISPR Cas9 (to improve desired targeting) or against harmful CRISPR Cas9 components (already active in a patient) is also disclosed. The peptides combined with a delivery system is also disclosed.Type: GrantFiled: May 6, 2020Date of Patent: June 4, 2024Assignee: National Technology & Engineering Solutions of Sandia, LLCInventors: Brooke Nicole Harmon, Yooli Kim Light, Mary Bao Tran-Gyamfi, Joseph S. Schoeniger, Edwin A. Saada, Kenneth L. Sale
-
Patent number: 11992514Abstract: Ready-to-use liquid bivalirudin compositions, methods of using the ready-to-use bivalirudin compositions, and methods of preparing the ready-to-use liquid bivalirudin compositions are provided herein. The liquid ready-to-use bivalirudin compositions comprise a pharmaceutically acceptable amount of bivalirudin.Type: GrantFiled: May 20, 2019Date of Patent: May 28, 2024Assignee: MAIA PHARMACEUTICALS, INC.Inventor: Srikanth Sundaram
-
Patent number: 11952433Abstract: The present disclosure relates to a heterochiral peptide complex, a self-assembled intermediate thereof, an alignment medium composition used for nuclear magnetic resonance spectroscopy residual dipolar coupling (NMR-RDC) measurement, which includes the same, and a method for NMR measurement for a biomolecule. Since the heterochiral peptide complex contains a ?-sheet peptide and has superior structural stability against environmental factors such as heat, acidity and ionic strength, it is applicable as an alignment medium for measuring RDC for various biomolecules.Type: GrantFiled: January 20, 2021Date of Patent: April 9, 2024Assignee: INDUSTRY ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITYInventors: Yong-Beom Lim, Hye Soo Lee
-
Patent number: 11939399Abstract: A synthetic peptide sp4 has an amino acid sequence shown in SEQ ID NO: 1. As the sole effective ingredient in the antitumor efficacy test, it has a significant inhibitory effect on both the tumor volume and tumor weight of human osteosarcoma MG-63 in nude mice and has a significant dose-effect and time-effect relationship. There is no difference between the relative tumor growth rate T/C (%) of sp4 and that of the positive control group of Paclitaxel. The safety of sp4 is that its maximal tolerated dose for intravenous administration is 700 mg/kgBW. Sp4 has clear targets of pharmacological effects, while having efficacy in vivo, it also has an inhibitory effect on tumor telomerase, has an arrest on G1 phase of the tumor cell cycle, and inhibits the high expressions of tumor PD-L1 and CD47. The present disclosure relates to multiple uses of sp4, especially in the preparation of a class of antitumor drugs.Type: GrantFiled: March 24, 2022Date of Patent: March 26, 2024Assignee: TAIAN CITY QIHANG BIOTECHNOLOGY CO.Inventors: Wanqin Zhang, Yintian Li, Xuewen Ji, Limei Zhao
-
Patent number: 11939398Abstract: The invention relates to neurodegenerative disorders, and in particular to novel peptides, peptidomimetics, compositions, therapies and methods for treating such conditions, for example Alzheimer's disease.Type: GrantFiled: August 16, 2017Date of Patent: March 26, 2024Assignee: Neuro-Bio LtdInventors: Susan Greenfield, Sara Garcia-Rates, Jesus Seco Moral, Roger Prades Cosano